The Magazine for Sleep Professionals
Wednesday, November 11, 2026
It’s a very exciting time in narcolepsy research, particularly on two fronts: better understanding the complexities of the disorder and developing more targeted treatments. With so many advances underway, it can feel overwhelming to keep track of research developments and understand how the pieces fit together. This can be especially […]
Out of my 25 years as a certified physician assistant, I’ve spent 15 working in sleep medicine. For much of that time, I’ve had a burr under my saddle. What is that burr? It’s that sleep medicine is not simply sleep apnea medicine. There are approximately 80 or so sleep […]
ProSomnus Sleep Technologies announced the formation of its inaugural Medical Advisory Board, significant enhancements to its RPMO₂ platform, and growing clinical evidence supporting precision oral appliance therapy (OAT), including results from the FLOSAT study. These advancements will be highlighted during the company’s participation at CHEST 2026, October 19-21, 2026, in […]
Alkermes plc announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society’s (ESRS) 28th Congress, Sleep Europe 2026, taking place Oct. 20-23, 2026 in Maastricht, the Netherlands. The company will present new data related to LUMRYZ® […]
Takeda announced that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the […]
My training for positive airway pressure (PAP) setup started with a few days of shadowing another employee at the durable medical equipment (DME) supplier where I worked. After that, I was handed a script to follow and a list of boxes to check during every setup. It covered how the […]
Carnyx Therapeutics Ltd. unveiled CNYX-005, its lead oral sleep candidate, alongside preclinical findings showing increased total sleep time and non-rapid eye movement (NREM) sleep in aged animal models. In the study, aged rats administered with CNYX-005 showed an approximately 1.5- to 2-hour increase in total sleep time compared to the control […]
Mosanna Therapeutics, Inc., announced results from its Phase 1 MOSAIC study. MOS118 was safe and well tolerated across all doses, with no serious adverse events reported. These results support progression of the study into patients with OSA. “With these results we can now proceed to evaluate MOS118 in the patients it […]
Sleep problems are common in middle age, particularly among women in their 40s and 50s. In a new study published on September 1, 2026, in Journal of Wood Science, the researchers explored whether essential oils derived from Hinoki (Chamaecyparis obtusa), known as Japanese cypress, roots could help improve sleep quality. […]
Vanda Pharmaceuticals Inc. announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). Vanda intends to discuss these data with the U.S. Food and Drug Administration (FDA) and to submit a supplemental New Drug Application (sNDA) seeking […]
